Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70059 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Margareth C Ozelo und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Campinas, Hemocentro UNICAMP, Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Polyethylene Glycols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A.
Objective
Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to polyethylene glycol, in children aged 7 to < 12 years with severe haemophilia A.
Methods
Alfa‐PROTECT is a phase 3, multicentre, open‐label, single‐arm study (NCT05147662). Primary endpoint was the incidence of adverse events of special interest (AESI) leading to discontinuation during the first 4 exposure days.
Results
Overall, 35 children enrolled; 32 completed the 6‐month study, 21 (60%) reported ≥ 1 AE. Median (range) treatment duration was 182 (172–198) days. All AEs were mild/moderate; 3/35 children (8.6%) had study drug‐related AEs. One (2.9%) LoE event was considered an AESI, and led to temporary treatment interruption. No AEs resulted in study drug discontinuation. The probability of < 5% of patients experiencing an AESI was 92.2%. Bleed protection was maintained with damoctocog alfa pegol prophylaxis.
Conclusions
These data confirm the safety profile of damoctocog alfa pegol in children aged 7 to < 12 years with severe haemophilia A. Secondary endpoints indicate treatment was efficacious. Trial Registration The Alfa‐PROTECT trial is registered at ClinicalTrial.gov (NCT05147662)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Campinas, Hemocentro UNICAMP, Campinas, São Paulo, Brazil.
- Bambino Gesù Children's Hospital, Rome, Italy.
- National Center for Rare Disorders and Department of Paediatric Research, Oslo University Hospital, Oslo, Norway.
- Department of Pediatrics, Ege University Faculty of Medicine, Bornova, Turkey.
- Department of Pediatrics, McMaster Centre for Transfusion Research, McMaster Children's Hospital/McMaster University, Hamilton, Ontario, Canada.
- Bayer AG, London, UK.
ORCID-Profile: Margareth C Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C Makris, Monika Maas Enriquez, Luciana C Oliveira, Mario Guillermo Arbesú, Mauro Davoli, Anthony K C Chan, Maria E Mancuso
Förderung
- Bayer
Zitieren
APA
Ozelo, M. C., Luciani, M., Glosli, H., Kavakli, K., Samji, N., Makris, G. C., Tueckmantel, C., Maas Enriquez, M., Oliveira, L. C., Gupta, S., Arbesú, M. G., Davoli, M., Chan, A. K. C., & Mancuso, M. E. (2026). Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70059
Vancouver
Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, et al. Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70059
BibTeX
@article{Ozelo2026,
author = {Ozelo, Margareth C and Luciani, Matteo and Glosli, Heidi and Kavakli, Kaan and Samji, Nasrin and Makris, Gregory C and Tueckmantel, Claudia and Maas Enriquez, Monika and Oliveira, Luciana C and Gupta, Shveta and Arbesú, Mario Guillermo and Davoli, Mauro and Chan, Anthony K C and Mancuso, Maria E},
title = {Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70059}
}
EUVIMED